NO20001515L - Vitronektin reseptor-antagonist - Google Patents

Vitronektin reseptor-antagonist

Info

Publication number
NO20001515L
NO20001515L NO20001515A NO20001515A NO20001515L NO 20001515 L NO20001515 L NO 20001515L NO 20001515 A NO20001515 A NO 20001515A NO 20001515 A NO20001515 A NO 20001515A NO 20001515 L NO20001515 L NO 20001515L
Authority
NO
Norway
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
NO20001515A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001515D0 (no
Inventor
William E Bondinelli
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20001515L publication Critical patent/NO20001515L/no
Publication of NO20001515D0 publication Critical patent/NO20001515D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20001515A 1997-09-24 2000-03-23 Vitronektin reseptor-antagonist NO20001515D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5986797P 1997-09-24 1997-09-24
PCT/US1998/019987 WO1999015178A1 (fr) 1997-09-24 1998-09-24 Antagoniste du recepteur de la vitronectine

Publications (2)

Publication Number Publication Date
NO20001515L true NO20001515L (no) 2000-03-23
NO20001515D0 NO20001515D0 (no) 2000-03-23

Family

ID=22025805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001515A NO20001515D0 (no) 1997-09-24 2000-03-23 Vitronektin reseptor-antagonist

Country Status (13)

Country Link
EP (1) EP1023073A1 (fr)
JP (1) JP2002500162A (fr)
KR (1) KR20010024249A (fr)
CN (1) CN1271284A (fr)
AU (1) AU9578798A (fr)
BR (1) BR9813214A (fr)
CA (1) CA2304000A1 (fr)
HU (1) HUP0003931A2 (fr)
IL (1) IL135188A0 (fr)
NO (1) NO20001515D0 (fr)
PL (1) PL339414A1 (fr)
TR (1) TR200000786T2 (fr)
WO (1) WO1999015178A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358855A1 (fr) 1999-02-03 2000-08-10 Merck & Co., Inc. Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
WO2002085405A2 (fr) 2001-04-24 2002-10-31 Merck Patent Gmbh POLYTHERAPIE A BASE D'AGENTS ANTIANGIOGENIQUES ET DE FACTEUR DE NECROSE TUMORALE TNF$g(a)
EP1443963B1 (fr) 2001-10-22 2014-05-21 The Scripps Research Institute Composes de ciblage d'anticorps
WO2004089890A2 (fr) * 2003-04-04 2004-10-21 Smithkline Beecham Corporation Procede et produits intermediaires pour preparer des benzazepines
CA2554644C (fr) 2004-02-02 2015-06-16 Pioneer Hi-Bred International, Inc. Facteur de transcription odp2 (ovule development protein 2) du domaine ap2 et procedes pour l'utiliser
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
CN101588812A (zh) 2007-01-18 2009-11-25 默克专利有限公司 使用整联蛋白配体治疗癌的特异疗法和药物
AU2008321770B2 (en) 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
EP2257538B1 (fr) * 2008-03-06 2016-04-27 GlaxoSmithKline LLC Procédé pour la préparation de dérivés de benzadiazépine
EP2395992A2 (fr) 2009-02-10 2011-12-21 The Scripps Research Institute Vaccination programmée chimiquement
CN102427816A (zh) 2009-03-30 2012-04-25 宇部兴产株式会社 用于治疗或预防眼病的药物组合物
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
US8704041B2 (en) 2009-12-30 2014-04-22 Pioneer Hi Bred International Inc Methods and compositions for targeted polynucleotide modification
AU2010339404B2 (en) 2009-12-30 2016-01-28 Pioneer Hi-Bred International, Inc. Methods and compositions for the introduction and regulated expression of genes in plants
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
CA2304000A1 (fr) 1999-04-01
JP2002500162A (ja) 2002-01-08
WO1999015178A1 (fr) 1999-04-01
PL339414A1 (en) 2000-12-18
NO20001515D0 (no) 2000-03-23
HUP0003931A2 (hu) 2001-10-28
BR9813214A (pt) 2000-08-29
TR200000786T2 (tr) 2000-08-21
IL135188A0 (en) 2001-05-20
KR20010024249A (ko) 2001-03-26
AU9578798A (en) 1999-04-12
CN1271284A (zh) 2000-10-25
EP1023073A1 (fr) 2000-08-02

Similar Documents

Publication Publication Date Title
NO20001515L (no) Vitronektin reseptor-antagonist
NO20001514L (no) Vitronectin-reseptor-antagonist
NO983002L (no) Vitronectin-reseptor-antagonister
NO983003L (no) Vitronectin-reseptor-antagonister
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
DK0896533T3 (da) Pentafluorbenzensulfonamider og analoger
ATE306261T1 (de) Antithrombosemittel
GB9514473D0 (en) Chemical compounds
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
SG44989A1 (en) Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman
AU2002213421A1 (en) Condensed pyridoindole derivatives
NO943687D0 (no) 4-(4'-piperidinyl eller 3'-pirrolidinyl) substituerte imidazoler som H3-reseptorantagonister og terapeutiske anvendelser derav
BR9812340A (pt) Antagonistas de receptor de vitronectina
ATE240339T1 (de) Nukleotidanaloga
ATE267602T1 (de) 2-methyl-thieno-benzodiazepin-formulierung
AP1534A (en) Vitronectin receptor antagonists.
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
NO20033184D0 (no) Anvendelse av forbindelsen (+)-<alfa>-(2,3-dimetoksyfenyl)-1- [2-(4-fluorfenyl)etyl]-4-piperidinmetanol
WO1998031704A3 (fr) Antagonistes de tachykinine
WO2001017959A3 (fr) Antagonistes du recepteur de la vitronectine
NO20004545D0 (no) FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol
WO2000007544A3 (fr) Antagonistes du recepteur de la proteine s
DK0980383T3 (da) Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener
NO964921D0 (no) Mellomprodukt for fremstilling av farmasöytisk aktiv forbindelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application